CLINICAL AND LABORATORY EVALUATION OF COMBINED APPLICATION OF ADAMANTANES AND ETIOPATHOGENETIC DRUGS IN INFLUENZA AND ACUTE RESPIRATORY VIRAL INFECTIONS IN CHILDREN

The clinical and laboratory efficacy and safety of combined use of the antiviral pharmaceutical product (Adamantine family) and the complex preparation for etiopathogenetic therapy of influenza and ARVI in children were examined in the prospective clinical trial. The trial involved 90 randomized into 2 groups children aged 2-6 years with verified diagnoses of influenza and ARVI. Patients of the first group received the drug "Citovir^®-3", children of the second group received combined therapy ("Citovir^®-3" + "Orvirem^®"). Evaluation of the efficacy and safety of the investigational drugs was performed by means of comparative intergroup statistical analysis of generally accepted for such nosology clinical signs and laboratory findings, frequency and severity of adverse events. The analysis of the results revealed that the use of "Citovir^®-3" as a monotherapy and in combination with "Orvirem^®" contributes to the reduction of the main manifestations of infectious process without statistically significant intergroup differences. Monotherapy with "Citovir^®-3" leaded to a more pronounced increase in the level of secretory immunoglobulin A in the entrance gate of infection (saliva) and α-interferon in the serum. During the clinical trial no adverse events and abnormal laboratory findings were found in the comparative groups. The efficacy and safety of combined use of "Citovir^®-3" and "Orvirem^®" allow us to recommend this combination for treatment of verified influenza A in children aged 2-6 years. For the treatment of ARVI of another etiology, the combined use of the investigational drugs has no advantage as compared to the monotherapy with "Citovir^®-3".

грипп, ОРВИ, дети, адаминтаны, этиопатогенетическое лечение, influenza, ARVI, children, adamantans, etiopathogenetic treatment